Core Insights - WuXi AppTec reported a significant increase in performance, with a 18.61% year-on-year growth in revenue for the first three quarters of 2025, reaching 32.857 billion yuan, and a net profit of 12.076 billion yuan, marking an 84.84% increase year-on-year [2][3] Revenue Breakdown - The company achieved a total revenue of 32.857 billion yuan in the first three quarters of 2025, with the following contributions: - Chemical business revenue: 25.98 billion yuan, up 29.3% year-on-year - Small molecule D&M business revenue: 14.24 billion yuan, up 14.1% year-on-year - Testing business revenue: 4.17 billion yuan - Laboratory analysis and testing revenue: 2.96 billion yuan, up 2.7% year-on-year - Biological business revenue: 1.95 billion yuan, up 6.6% year-on-year [2] Client Revenue Distribution - Revenue from different regions for the first three quarters of 2025: - Revenue from U.S. clients: 22.15 billion yuan, up 31.9% year-on-year - Revenue from European clients: 3.84 billion yuan, up 13.5% year-on-year - Revenue from Chinese clients: 5.04 billion yuan, up 0.5% year-on-year - Revenue from other regions: 1.42 billion yuan, up 9.2% year-on-year [2] Business Strategy and Outlook - The growth in performance is attributed to the company's focus on the CRDMO business model, improved production efficiency, and increased capacity utilization from large-scale projects. The company expects a return to double-digit growth in continuous operations revenue, raising the growth forecast from 13%-17% to 17%-18% [3] - The overall revenue forecast for the year has been adjusted from 42.5 billion - 43.5 billion yuan to 43.5 billion - 44 billion yuan [3] Equity Transfer - The company announced a plan to transfer 100% equity of two subsidiaries for a base price of 2.8 billion yuan to Shanghai Shihe Rong Enterprise Management Consulting Co., Ltd. and Shanghai Shihe Mu Enterprise Management Consulting Co., Ltd. [3] - The acquiring parties are newly established companies under Hillhouse Capital, which have good financial status and creditworthiness [4]
药明康德前三季净利超120亿元 在手订单近600亿元